Ibandronate

Generic Name: Ibandronate

Brand Names: Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva

Drug Type: Small Molecule

Chemical Formula: C_₉H_₂₃NO_₇P_₂

CAS Number: 114084-78-5

Unique Ingredient Identifier: UMD7G2653W

Background: Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.

Ibandronate was granted FDA approval on 16 May 2003.

Indication: For the treatment and prevention of osteoporosis in postmenopausal women.

Associated Conditions: Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis

Clinical Trials

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.

Phase 2

Completed

Conditions: Pain; Bone Neoplasms; Neoplasm Metastasis

Interventions: Drug: ibandronate [Bondronat]

First Posted Date: 2007-07-18

Last Posted Date: 2014-01-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 13

Registration Number: NCT00502736

A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Conditions: Postmenopausal Osteoporosis

First Posted Date: 2007-06-28

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00493532

BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]
Drug: Placebo

First Posted Date: 2007-06-28

Last Posted Date: 2016-03-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 68

Registration Number: NCT00493623

Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

Phase 4

Terminated

Conditions: Lung Cancer

Interventions: Drug: Ibandronate (Bondronat)

First Posted Date: 2007-06-27

Last Posted Date: 2016-02-17

Lead Sponsor: Chinese Society of Lung Cancer

Target Recruit Count: 20

Registration Number: NCT00492843

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Shanghai Chest Hospital, Shanghai, China

and more 5 locations

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.

Phase 2

Withdrawn

Conditions: Pain
Neoplasm Metastasis
Bone Neoplasm

Interventions: Drug: ibandronate [Bondronat]

First Posted Date: 2007-05-24

Last Posted Date: 2017-08-16

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00478270

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density

Phase 4

Terminated

Conditions: Osteoporosis

Interventions: Drug: teriparatide
Drug: ibandronate

First Posted Date: 2007-03-13

Last Posted Date: 2014-10-29

Lead Sponsor: Papageorgiou General Hospital

Target Recruit Count: 19

Registration Number: NCT00446589

Locations: 🇬🇷
Papageorgiou General Hospital, Thessaloniki, Greece

Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.

Phase 2

Conditions: Renal Transplant

Interventions: Drug: Placebo
Drug: Ibandronate

First Posted Date: 2007-01-18

Last Posted Date: 2010-03-24

Lead Sponsor: Smerud Medical Research International AS

Target Recruit Count: 130

Registration Number: NCT00423384

Locations: 🇳🇴
Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway

Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis

Phase 4

Completed

Conditions: Osteoporosis, Postmenopausal

First Posted Date: 2006-11-30

Last Posted Date: 2018-06-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 365

Registration Number: NCT00405392

The Effect Of Oral Ibandronate In Male Osteoporosis

Phase 3

Completed

Conditions: Male Osteoporosis

Interventions: Drug: placebo
Drug: Ibandronate

First Posted Date: 2006-11-10

Last Posted Date: 2009-12-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 135

Registration Number: NCT00397839

Locations: 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States

Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients

Phase 2

Conditions: Breast Cancer

First Posted Date: 2006-09-27

Last Posted Date: 2006-12-04

Lead Sponsor: University of Turku

Target Recruit Count: 60

Registration Number: NCT00381368

Locations: 🇫🇮
Dept of Oncology, Helsinki University Central Hospital, Helsinki, Finland
🇫🇮
Dept of Oncology, Tampere University Hospital, Tampere, Finland
🇫🇮
Dept of Oncology, Oulu University Hospital, Oulu, Finland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy